{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T06:39:23.016568+00:00","company":{"ticker":"TWST","cik":1581280,"company_name":"Twist Bioscience Corp"},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"f0fe18472df0afca1aa065a5843b67fabba5e2e5","cik":1581280,"ticker":"TWST","company_name":"Twist Bioscience Corp","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":"$0.71 per share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$44.0 million","period_text":"fiscal second quarter 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$110.7 million"},"claim":"Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.","evidence_excerpt":"expressly set forth by specific reference in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nTwist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001581280-26-000037","anchor_url":"https://secwatch.observer/filing/0001581280-26-000037#claim-f0fe18472df0afca1aa065a5843b67fabba5e2e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/0001581280-26-000037-index.htm"},{"fact_type":"earnings_release","fact_key":"c175a1c546b8b78014a37c158d0239a8cf4a6fe1","cik":1581280,"ticker":"TWST","company_name":"Twist Bioscience Corp","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal year 2024","report_date":"2024-05-02","result_type":"guidance_update","revenue_text":"$300M to $304M"},"claim":"Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.","evidence_excerpt":"— Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-24-019999","anchor_url":"https://secwatch.observer/filing/0001628280-24-019999#claim-c175a1c546b8b78014a37c158d0239a8cf4a6fe1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm"},{"fact_type":"earnings_release","fact_key":"fc462f1c5e1adcab94cda444814c1e4bda35b3a0","cik":1581280,"ticker":"TWST","company_name":"Twist Bioscience Corp","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"-$0.79","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"-$45.5 million","period_text":"fiscal second quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$75.3 million"},"claim":"Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.","evidence_excerpt":"FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001628280-24-019999","anchor_url":"https://secwatch.observer/filing/0001628280-24-019999#claim-fc462f1c5e1adcab94cda444814c1e4bda35b3a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024019999/0001628280-24-019999-index.htm"}]}